Retatrutide Dysesthesia: Tingling/Burning Explained

Dysesthesia, an abnormal sensation described as tingling, burning, prickling, or "pins and needles," is a relatively unique side effect reported with retatrutide that is less common with semaglutide or tirzepatide. This side effect appears to be related to the triple agonist's glucagon receptor activation and emerged as a notable finding in the Phase 2 trial (Jastreboff et al., NEJM 2023). Understanding what causes it and how to manage it helps patients navigate this unusual but generally benign symptom.

What Dysesthesia Feels Like

Patients describe dysesthesia in various ways, and the sensation can differ from person to person:

• Tingling or "pins and needles" sensation, often in extremities
• Burning or warmth in skin areas without visible redness
• Prickling or "crawling" sensation on the skin
• Heightened sensitivity to touch (even light touch feels uncomfortable)
• Brief "electric" sensations

These sensations are typically intermittent rather than constant, mild to moderate in severity, and not associated with weakness, numbness, or loss of function. If you experience persistent numbness, weakness, or loss of sensation, these are different symptoms that warrant prompt medical evaluation.

Why Retatrutide Causes Dysesthesia

The leading hypothesis is that glucagon receptor activation is responsible. Glucagon receptors are expressed on peripheral nerves, and their activation may transiently alter nerve signaling. This would explain why dysesthesia is more commonly reported with retatrutide (a glucagon agonist) than with semaglutide or tirzepatide (which do not activate glucagon receptors).

Additional contributing factors may include rapid metabolic changes from the triple agonist effect, vitamin and mineral shifts associated with reduced food intake (particularly B vitamins and electrolytes), and transient changes in blood sugar that affect nerve function.

Phase 2 Trial Data

In the Phase 2 trial, dysesthesia was reported at higher rates in retatrutide groups compared to placebo, particularly at higher doses. The exact rates were not among the most prominently reported side effects (GI effects dominated), but the signal was noted as a finding of interest. Most cases were graded as mild and did not lead to treatment discontinuation.

When It Typically Occurs

Management Strategies

• Nutritional support: Ensure adequate B-vitamin intake (particularly B12 and B6), magnesium, and potassium. Deficiencies in these nutrients can exacerbate nerve sensitivity.
• Hydration: Dehydration can worsen nerve symptoms. Maintain at least 64 oz of water daily.
• Blood sugar stability: Avoid extremes of blood sugar. Eat regular, balanced meals even with reduced appetite.
• Time: Most dysesthesia improves with continued treatment as the body adapts to glucagon receptor activation.
• Dose adjustment: If symptoms are severe, your provider may recommend slowing titration or reducing dose temporarily.
• Rule out other causes: Persistent or worsening symptoms should be evaluated to rule out diabetic neuropathy, B12 deficiency, carpal tunnel, or other neurological conditions.

Dysesthesia vs. Diabetic Neuropathy

For patients with diabetes, it is important to distinguish retatrutide-related dysesthesia from diabetic neuropathy. Key differences: retatrutide dysesthesia tends to be intermittent, not position-dependent, and improves over time, while diabetic neuropathy is typically persistent, worse in feet and hands, worsens at night, and progresses without treatment. If you have diabetes and develop new tingling or burning, have your provider evaluate whether this is a medication effect or underlying neuropathy requiring separate treatment.

When to Be Concerned

• Symptoms that are progressive (worsening over weeks rather than improving)
• Numbness or loss of sensation (different from tingling/burning)
• Muscle weakness associated with the sensations
• Symptoms confined to one side of the body (could indicate a neurological issue)
• Vision changes accompanying the sensations

GLP-1 Treatment With Side Effect Management

Trimi provides compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with medical teams who monitor and manage all side effects. Learn how Trimi works.

Frequently Asked Questions

Is retatrutide dysesthesia permanent?

No. In the Phase 2 trial, dysesthesia was generally transient and resolved with continued treatment or dose adjustment. Permanent nerve damage from retatrutide has not been reported.

Does semaglutide also cause tingling?

Dysesthesia is rare with semaglutide and tirzepatide. It appears to be more specific to retatrutide, likely due to the glucagon receptor activation that these other medications lack.

Should I stop retatrutide if I have tingling?

Mild, intermittent tingling that is not worsening does not usually require discontinuation. However, discuss all new symptoms with your provider so they can assess whether the sensation is expected or requires further evaluation.

Can supplements help with retatrutide dysesthesia?

B-complex vitamins, magnesium, and alpha-lipoic acid may help support nerve function. However, supplements should complement medical evaluation, not replace it. Have your provider check B12 and electrolyte levels before supplementing.